Литература

1. Soni A. J., Modi G. Outcome of uncorrected CSF leak and consequent recurrent meningitis in a patient: a case presentation and literature review//British journal of neurosurgery. - 2020. - Т. 34. - N. 5. - С. 492 - 494. DOI: 10.1080/02688697.2018.1478063.

2. Shizawa K. et al. The Examination of Prognostic Factors and Treatment Strategies for Traumatic Cerebrospinal Fluid Leakage//Cureus. - 2024. - Т. 16. - N. 1. DOI: 10.7759/cureus.52874.

3. Liao K. H. et al. Risk of death in patients with post-traumatic cerebrospinal fluid leakage-analysis of 1773 cases//Journal of the Chinese Medical Association. - 2016. - Т. 79. - N. 2. - С. 58 - 64. DOI: 10.1016/j.jcma.2015.10.002.

4. Oh J. W., Kim S. H., Whang K. Traumatic cerebrospinal fluid leak: diagnosis and management//Korean journal of neurotrauma. - 2017. - Т. 13. - N. 2. - С. 63. DOI: 10.13004/kjnt.2017.13.2.63.

5. Zainel A., Mitchell H., Sadarangani M. Bacterial meningitis in children: neurological complications, associated risk factors, and prevention//Microorganisms. - 2021. - Т. 9. - N. 3. - С. 535. DOI: 10.3390/microorganisms9030535.

6. R. et al. Incidencia de hospitalizaciones por enfermedad en con condiciones de riesgo en (2005 - 2012)//Enfermedades Infecciosas y . - 2016. - Т. 34. - N. 5. - С. 293 - 297. DOI: 10.1016/j.eimc.2015.07.006.

7. Bennett N. M. et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). - 2012.

8. Tomczyk S. et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >= 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)//MMWR Morb Mortal Wkly Rep. - 2014. - Т. 63. - N. 37. - С. 822-5.

9. Matanock A. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >= 65 years: updated recommendations of the Advisory Committee on Immunization Practices//MMWR. Morbidity and mortality weekly report. - 2019. - Т. 68. DOI: 10.15585/mmwr.mm6846a5.

10. Bennett N. M. et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6 - 18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)//Morbidity and Mortality Weekly Report. - 2013. - Т. 62. - N. 25. - С. 521.

11. Koelman D. L. H., Brouwer M. C., van de Beek D. Resurgence of pneumococcal meningitis in Europe and Northern America//Clinical microbiology and infection. - 2020. - Т. 26. - N. 2. - С. 199 - 204. DOI: 10.1016/j.cmi.2019.04.032.

12. Ouldali N. et al. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study//The Lancet Infectious Diseases. - 2021. - Т. 21. - N. 1. - С. 137 - 147. DOI: 10.1016/S1473-3099(20)30165-1.

13. Regev-Yochay G. et al. Pneumococcal meningitis in adults after introduction of PCV7 and PCV13, Israel, July 2009 - June 2015//Emerging Infectious Diseases. - 2018. - Т. 24. - N. 7. - С. 1275. DOI: 10.3201/eid2407.170721.

14. Cohen-Inbar O. et al. Vaccination as primary prevention? The effect of anti-pneumococcal vaccination on the outcome of patients suffering traumatic skull base fractures//Journal of Neurosurgical Sciences. - 2015. - Т. 61. - N. 3. - С. 245-255. DOI: 10.23736/S0390-5616.16.03287-X.

15. Leibu S. et al. Clinical significance of long-term follow-up of children with posttraumatic skull base fracture//World Neurosurgery. - 2017. - Т. 103. - С. 315 - 321. DOI: 10.1016/j.wneu.2017.04.068.